BRAF and cancer: Among them, N-RAS, the first oncogene identified in melanoma, and B-RAF are also considered important therapeutic targets because it has been shown that one-third of all human cancers have oncogenic mutations in the small GTPase RAS family, which may therefore play a pivotal role in tumorigenesis [22].